凯盛新材(301069) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥235,849,304.65, a decrease of 0.55% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥30,560,405.53, down 46.87% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥29,650,209.50, a decline of 47.72% compared to the previous year[5]. - The net cash flow from operating activities was -¥49,889,728.33, a significant decrease of 266.26%[5]. - Operating revenue for the period was CNY 727,822,965.45, down from CNY 760,644,804.55 in the previous period, reflecting a decrease of approximately 4.3%[22]. - Net profit for the period was CNY 153,396,772.07, down from CNY 219,122,005.91 in the previous period, a decline of approximately 30%[22]. - The net profit for Q3 2023 was CNY 133,333,903.69, a decrease of 29.3% compared to CNY 188,770,346.75 in Q3 2022[23]. - The total revenue from operating activities was CNY 384,100,990.16, down 13.0% from CNY 441,481,794.28 in the same period last year[25]. - The company reported a total profit of CNY 153,048,280.35 for Q3 2023, down from CNY 218,482,166.66 in Q3 2022[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,797,987,102.57, an increase of 7.76% from the end of the previous year[5]. - Total assets increased to CNY 1,797,987,102.57 as of September 30, 2023, up from CNY 1,668,525,610.49 at the beginning of the year, representing a growth of approximately 7.8%[20]. - Current assets totaled CNY 806,534,106.80, an increase of 8.3% from CNY 744,858,108.81 at the start of the year[20]. - Total liabilities rose to CNY 303,301,288.32, compared to CNY 247,635,312.42 at the beginning of the year, marking an increase of about 22.5%[21]. - The company reported a decrease in accounts payable to CNY 177,492,102.14 from CNY 200,438,169.34, a reduction of approximately 11.4%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19.19 million[14]. - The largest shareholder, Huabang Life Health, holds 44.51% of shares, totaling 187,216,000 shares[14]. - The second-largest shareholder, Zibo Kaisheng Investment Management Center, holds 6.79% of shares, totaling 28,571,200 shares[14]. - The total number of restricted shares at the end of the period is 280,200,000 shares, with no new restrictions added during the period[16]. - Wang Jiarong and Wang Yong, both significant shareholders, hold 3.80% and 3.73% of shares respectively, totaling 16,000,000 and 15,680,000 shares[14]. Cash Flow and Investments - The cash and cash equivalents at the end of the period stood at CNY 254,209,285.82, a decrease from CNY 321,201,069.21 at the end of Q3 2022[26]. - The cash inflow from investment activities was CNY 528,289,586.87, significantly lower than CNY 1,777,145,803.50 in the previous year[25]. - The cash outflow from investment activities was CNY 404,709,564.61, compared to CNY 1,581,726,104.49 in Q3 2022[25]. - The cash flow from financing activities was negative at CNY -63,096,000.00, compared to CNY -105,160,000.00 in the same period last year[26]. Expenses and Taxation - Operating costs increased to CNY 578,530,132.45, compared to CNY 548,587,627.42 in the previous period, indicating a rise of about 5.5%[22]. - Research and development expenses increased to CNY 38,118,847.77, compared to CNY 31,628,331.29 in the previous period, representing a growth of about 20.5%[22]. - The income tax expense decreased by ¥9,997,400, a reduction of 33.65% due to lower profits[12]. Other Information - The company has no new important matters to report for the quarter[18]. - The company has not disclosed any new product or technology developments in the current report[18]. - The report indicates no participation in margin trading by the top shareholders[15]. - The company has not reported any mergers or acquisitions in the current quarter[18]. - The company did not report any new product launches or significant market expansion strategies during the quarter[27].